Could Actio’s KCNT1 epilepsy drug become an ultra-rare disease test case for the FDA?
Ultra-rare epilepsy has few paths forward. Actio’s ABS-1230 now tests whether precision genetics can reshape FDA evidence standards.
Pharma & Biotech